Stryker Corporation
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total net sales (FY2025) | $25.1 billion ($25,116M), up 11.2% year-over-year (reported) |
| Organic sales growth (FY2025) | +10.3% year-over-year |
| Net earnings (FY2025) | $3.25 billion ($3,246M), up 8.5% year-over-year |
| Diluted EPS (GAAP, FY2025) | $8.40, up 8.2% year-over-year |
| Adjusted EPS (non-GAAP, FY2025) | $13.63, up 11.8% year-over-year |
| Adjusted operating margin (FY2025) | 26.3%, up ~100 basis points year-over-year |
| R&D expense (FY2025) | $1.6 billion ($1,623M), up 10.7% year-over-year |
| Major acquisition | Completed acquisition of Inari Medical, Inc. for approximately $4.9 billion (closed February 19, 2025), entering the peripheral vascular/venous thromboembolism market |
| Employees (as of Dec 31, 2025) | Approximately 56,000 employees worldwide |
| Reportable segments | Two: MedSurg and Neurotechnology; Orthopaedics |
Sources: Segment, geography, net sales, net earnings, EPS, organic growth, and R&D figures are company-disclosed, sourced from Stryker's 'Stryker Reports 2025 Operating Results and 2026 Outlook' earnings release (Exhibit 99.1 to Form 8-K, furnished ~January 29, 2026) covering Q4 and full-year 2025 vs. full-year 2024. Employee count (~56,000) is from Stryker's FY2025 Form 10-K. Full-year net sales for 2021-2023 are drawn from Stryker's respective prior-year earnings releases/10-Ks via financial-data aggregators and are rounded to the nearest $10 million; 2024 and 2025 figures are exact as reported. The Inari Medical acquisition value (~$4.9 billion) is as widely reported at deal announcement/close (company press releases, MedTech Dive, etc.). No third-party market-share estimates were used in this file.